Header Logo

Connection

SUSAN BLANEY to Quinolines

Back to Details
This is a "connection" page, showing publications SUSAN BLANEY has written about Quinolines.
SUSAN BLANEY
Connection Strength
0.133
Quinolines
  1. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
    View in: PubMed
    Score: 0.133
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.